La empresa
Dharmacon Research, Inc. fue fundada en 1995, y su principal producto era la síntesis de RNA mediante una nueva tecnología, llamada 2-ACE RNA. Más tarde, esta tecnología se convirtió en un estándar global para la síntesis de RNA.
A finales de los años 90, Dharmacon se especializó en una nueva e incipiente tecnología científica, el llamado silenciamiento génico. Lo hizo con su primer producto, el siGenome, que es un pequeño RNA de interferencia.
Dharmacon, es líder mundial en el suministro de oligonucleótidos RNA de alta calidad, de small interfering RNAs (siRNAs) y de una amplia gama de productos y tecnologías relacionados con interferencia de RNA (RNAi), de importante aplicación e introducción en investigación biotecnológica y farmacéutica.
Dharmacon pertenece al Horizon Discovery Group
Catálogos y Flyers
Videos
Welcome to Horizon Discovery, a PerkinElmer company
A complete overview of the Horizon Discovery product offerings including RNA synthesis and RNAi technologies via Dharmacon and continued innovation in CRISPR gene editing, cell line engineering, functional genomic screening, cell panel screening, and cell line derived reference standards. Additionally Horizon licenses a CHOSOURCE™ CHO-K1 GS knockout bioprocessing cell line and PinPoint™ base editing technology for therapeutic development.
A 2-minute intro to gene function studies
Learn more about Dharmacon solutions for gene function studies including RNAi, ORFs, and CRISPR technologies.
CRISPR-Cas9 format selection guide
Overwhelmed by the choices for gene editing reagents? Horizon Discovery walks you through all the options and helps you find what will be best for your CRISPR experiment.
What happens to the protein in a knockout cell line?
An overview of the possible fates of a protein after CRISPR knockout. This video covers how to validate your knockout cell line by combining techniques like western blotting and functional assays.
What is CRISPR interference or CRISPRi?
CRISPR interference (CRISPRi) a novel method for specific gene knockdown at the transcriptional level enabling scientists to better understand the biological pathways, processes and pathologies of disease. The Horizon CRISPRi system uses a deactivated Cas9 nuclease (dCas9) fused to our proprietary SALL1-SDS3 repressor construct to block transcription of target genes in combination with the first available synthetic single guide RNAs for CRISPRi.
¿Quieres visitar la web de Horizon?